Applied Therapeutics, Inc. (NASDAQ:APLT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Applied Therapeutics, Inc. (NASDAQ:APLT) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $6.10.

Separately, Royal Bank of Canada reissued a “sector perform” rating and set a $1.50 target price on shares of Applied Therapeutics in a research report on Wednesday, May 14th.

Applied Therapeutics Stock Performance

NASDAQ:APLT opened at $0.60 on Wednesday. The firm has a market cap of $85.36 million, a price-to-earnings ratio of -0.37 and a beta of 2.00. Applied Therapeutics has a 52 week low of $0.30 and a 52 week high of $10.62. The firm has a 50-day moving average price of $0.43 and a two-hundred day moving average price of $1.86.

Applied Therapeutics (NASDAQ:APLT) last posted its quarterly earnings data on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The business had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.61 million. As a group, sell-side analysts forecast that Applied Therapeutics will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. CreativeOne Wealth LLC grew its position in shares of Applied Therapeutics by 132.2% during the 1st quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company’s stock valued at $25,000 after acquiring an additional 28,701 shares during the period. Ground Swell Capital LLC bought a new position in Applied Therapeutics in the 4th quarter worth approximately $27,000. Toronto Dominion Bank bought a new position in Applied Therapeutics in the 4th quarter worth approximately $27,000. Private Advisor Group LLC bought a new position in Applied Therapeutics in the 4th quarter worth approximately $35,000. Finally, SG Americas Securities LLC boosted its holdings in Applied Therapeutics by 169.0% in the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock worth $35,000 after buying an additional 25,601 shares during the period. 98.31% of the stock is owned by institutional investors.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.